A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
Hypertension Research 39,
415 (June 2016). doi:10.1038/hr.2016.2
Authors: Yui Takeshige, Yoshihide Fujisawa, Asadur Rahman, Wararat Kittikulsuth, Daisuke Nakano, Hirohito Mori, Tsutomu Masaki, Koji Ohmori, Masakazu Kohno, Hiroaki Ogata & Akira Nishiyama
Source: Hypertension Research - Category: Cardiology Authors: Yui TakeshigeYoshihide FujisawaAsadur RahmanWararat KittikulsuthDaisuke NakanoHirohito MoriTsutomu MasakiKoji OhmoriMasakazu KohnoHiroaki OgataAkira Nishiyama Tags: circadian blood pressure empagliflozin obese sodium-glucose co-transporter 2 (SGLT2) urinary sodium excretion Source Type: research
More News: Cardiology | Eating Disorders & Weight Management | Empagliflozin | Hypertension | Jardiance | Obesity | SGLT2 Inhibitors | Sodium